Cycle length: 21 days. | |||
Drug | Dose and route | Administration | Given on days |
Rituximab | 375 mg/m2 IV* | Dilute in NS or D5W¶ to a final concentration of 1 to 4 mg/mL. Initial infusion: Start at 50 mg/hour; escalate in 50 mg/hour increments every 30 minutes to a maximum of 400 mg/hour, as tolerated.[2] In the absence of a severe infusion reaction, for subsequent infusions, administer 20% of the total dose over the first 30 minutes and the remaining 80% over 60 minutes, as tolerated. The 90-minute infusion schedule should not be used in patients who have clinically significant cardiovascular disease or a circulating lymphocyte count ≥5000/mm3. For patients not meeting these criteria, the recommended infusion rate for subsequent doses is 100 mg/hour, increased by 100 mg/hour every 30 minutes until a maximum infusion rate of 400 mg/hour is reached. | Day minus 2 of cycle 1 (48 hours prior to initiation of cycle 1), then day 1 of cycles 2 to 4 (four total doses). |
Ifosfamide | 5000 mg/m2 continuous IV infusion | Dilute in NS or D5W¶ to a final concentration of 0.6 to 20 mg/mL and infuse over 24 hours. | Day 4 |
MesnaΔ | 5000 mg/m2 continuous IV infusion | Add to ifosfamide bag and administer over 24 hours. Total concentration of mesna should not exceed 20 mg/mL. | Day 4 |
Carboplatin | AUC◊ = 5 mg/mL per min IV (maximum dose = 800 mg) | Dilute in 250 mL NS¶ and administer over 30 minutes. | Day 4 |
Etoposide | 100 mg/m2 IV daily | Dilute in 500 mL NS or D5W¶ to final concentration <0.4 mg/mL. Infuse over 30 to 60 minutes; if infused more rapidly, severe hypotension may occur. | Days 3 to 5 |
Pretreatment considerations: | |||
Emesis risk |
| ||
Hydration |
| ||
Prophylaxis for infusion reactions |
| ||
Infection prophylaxis |
| ||
Dose adjustment for baseline liver or kidney dysfunction |
| ||
Hepatitis screening |
| ||
Monitoring parameters: | |||
| |||
| |||
| |||
| |||
| |||
| |||
| |||
Suggested dose modifications for toxicity: | |||
Myelotoxicity |
| ||
Neurotoxicity |
| ||
Urotoxicity |
| ||
If there is a change in body weight of at least 10%, doses should be recalculated. |
ANC: absolute neutrophil count; AUC: area under the concentration × time curve; CBC: complete blood count; CNS: central nervous system; D5W: 5% dextrose in water; GFR: glomerular filtration rate; G-CSF: granulocyte colony stimulating factors; IV: intravenous; NCCN: National Comprehensive Cancer Network; NS: normal saline; RBC: red blood cell.
* A subcutaneous formulation (rituximab-hyaluronidase) that uses a shorter administration time is an acceptable alternative for patients who have tolerated at least one full dose of IV rituximab.[6] Dosing for the subcutaneous formulation varies by histology, and clinicians should refer to the United States Prescribing Information for details.
¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).
Δ Due to a longer half-life of ifosfamide and associated metabolites at higher doses, some references recommend continuation of mesna for 12 to 24 hours beyond completion of ifosfamide to reduce the risk of hemorrhagic cystitis. If necessary, oral mesna may be used at a dose twice that of IV mesna.
◊ AUC is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) × (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topics on dosing of anticancer agents in adults.
§ Consensus-based guidelines from the NCCN classify higher carboplatin doses (AUC ≥4) as highly emetogenic; by contrast, the American Society of Clinical Oncology and the Multinational Association for Supportive Care in Cancer guidelines consider all carboplatin doses to be moderately emetogenic. Although many institutions classify carboplatin-containing regimens as moderately emetogenic, a benefit for adding a neurokinin 1 receptor antagonist on day 1 has been shown in many studies; additional prophylaxis beyond day 1 for delayed emesis is not needed for most patients. Refer to UpToDate topics on prevention and treatment of chemotherapy-induced nausea and vomiting in adults.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟